Jeena Sikho Lifecare Employee Stock Options
Jeena Sikho Lifecare received BSE in-principle approval to list up to 6,50,000 ESOS 2024 shares. Both NSE and BSE approvals are now in place.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Jeena Sikho Lifecare received BSE in-principle approval to list up to 6,50,000 ESOS 2024 shares. Both NSE and BSE approvals are now in place.
Jeena Sikho Lifecare has launched two new Ayurvedic products, Acharya Ji's Amrit Tattava Vati and Acharya Ji's Oja Amrit Vati, in the domestic market.
Jeena Sikho Lifecare postponed its new Lucknow hospital's commercial operations to December 2026 from August. The delay stems from expanded work scope and adverse site weather.
Jeena Sikho Lifecare Limited received NABH accreditation for its Pune hospital, affirming its adherence to quality healthcare standards and operational excellence.
Jeena Sikho Lifecare launched two new Ayurvedic products, Jeevanodya Vati and Ojavardhan Vati. This expands the company's portfolio of healthcare and wellness offerings.
Jeena Sikho Lifecare Limited informed shareholders about the web-link to access its 2025-26 Annual Report and 9th AGM Notice.
Jeena Sikho Lifecare Limited will hold its 9th Annual General Meeting on September 28, 2026. The notice covers director appointments, reappointments, and a final dividend declaration.
Jeena Sikho is aggressively pivoting from low-margin government business to a high-margin cash-and-carry wellness ecosystem. Management is prioritizing operating leverage and 'prevention-first' health models to drive 30% annual growth.
JSLL reported Q1FY27 revenue of Rs 224.4 Cr (+29% YoY) with an EBITDA margin of 41%. The company is expanding its integrated Ayurveda model across 2,400 operational beds.
Jeena Sikho Lifecare Ltd reported revenue from operations of ₹224.4 Cr (+28.7% YoY) and net profit of ₹65.9 Cr (+28.5% YoY) for Q1 FY27.
Jeena Sikho delivered strong FY26 results with 71% revenue growth and 177% PAT growth, driven by hospital utilization and high-margin product sales. Management targets 4-5x PAT growth over 3-5 years.
Jeena Sikho reported stellar FY26 growth, pivoting from government to high-margin private patients. Management used flamboyant, messianic rhetoric to mask ₹21cr in one-time expenses related to auditor-mandated accounting changes and staff bonuses.
Jeena Sikho reported stellar FY26 performance with Revenue at ₹80,135 Lakhs and PAT at ₹22,218 Lakhs. The company expanded to 2,300 operational beds across 119 centers.
Jeena Sikho reported strong Q4FY26 results with a 55% YoY revenue surge, driven by expanding Ayurveda healthcare services and product reach.
Jeena Sikho Lifecare Ltd reported revenue from operations of ₹215.6 Cr (+54.8% YoY) and net profit of ₹45.1 Cr (+78.3% YoY) for Q4 FY26.